Figitumumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameFigitumumab
Drug Alias NameFigitumumab (Pfizer)芬妥木单抗菲吉妥木单抗Figitumumabum (Pfizer)Anti-IGF-1R monoclonal antibody (Pfizer) +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInsulin-like growth factor I receptor antagonists
TargetsInsulin-like growth factor I receptor
Therapy Area/IndicationsSolid tumoursProstatic NeoplasmsSmall Cell Lung Carcinoma +[15] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[40] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPfizer IncCliniques Universitaires Saint-Luc A.S.B.L.
Active IndicationsN/A
Inactive IndicationsSolid tumoursProstatic NeoplasmsSmall Cell Lung Carcinoma +[15] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG